ReviewThe Journal of pharmacy and pharmacology2015
The challenges in developing effective canine infectious respiratory disease vaccines.
Review in The Journal of pharmacy and pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- IFNL3 reduces replication of CIRDC-associated viruses in canine airway epithelial cells.Virus research · 2026Article
- A Novel Vitamin E Adjuvanted InjectableVaccines · 2026Article
- A targeted PCR approach for the detection of IOLA in canine infectious respiratory disease samples during an atypical CIRD outbreak in winter 2023.Frontiers in veterinary science · 2026Article
- Article
- Article
- One year duration of immunity of a combinationFrontiers in veterinary science · 2025Article
- Gram-positive enhancer matrix delivering FVpE via M cell targeting elicit protective mucosal and adaptive immune responses againstFrontiers in immunology · 2025Article
- Epidemiologic investigation and genetic characterization of canine respiratory coronavirus in the Southeastern United States.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2024Article
- Predominance of Canine Parainfluenza Virus andPathogens (Basel, Switzerland) · 2023Article
- Mucosal Vaccination with Live AttenuatedVaccines · 2023Article
- Canine Parainfluenza Virus Infection in a Dog with Acute Respiratory Disease.Veterinary sciences · 2022Article
- Thirteen-month duration of immunity of an oral canine vaccine against challenge withVeterinary record open · 2020Article
- Canine infectious respiratory disease: New insights into the etiology and epidemiology of associated pathogens.PloS one · 2019Article
- Parainfluenza virus 5-vectored vaccines against human and animal infectious diseases.Reviews in medical virology · 2018Review
- European surveillance of emerging pathogens associated with canine infectious respiratory disease.Veterinary microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCanine infectious respiratory disease (CIRD) is a disease of multifactorial aetiology, where multiple pathogens act sequentially or synergistically to cause disease. It is common within large dog populations, such as those in re-homing or training kennels. Vaccines are vital in its management of CIRD, but they often fail to prevent disease. Recently, a number of novel pathogens have been identified in CIRD outbreaks and represent new targets for vaccination. KEY
findingsInnate immune responses provide a vital first line of defence against the infectious agents involved in the development of CIRD. Once breeched, adaptive mucosal immunity is necessary to prevent infection and limit spread. Current vaccines target only a few of the agents involved in CIRD. Evidence, from the limited amount of published data, indicates that although vaccinating against these agents reduces infection rates, duration of shedding and severity of disease, it does not induce sterilising immunity; and this has important consequences for the management of the disease, and the future of CIRD vaccine development. SUMMARY: In the process of considering the development of novel CIRD vaccines, this paper focuses on the immunological mechanisms that provide protection for the respiratory tract, the current recommendations for canine vaccination, and the challenges surrounding existing CIRD vaccines, and their future development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.